NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Forecast & News

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its quarterly earnings data on Monday, November, 4th. The company reported $1.46 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.72 by $0.26. The company had revenue of $160.85 million for the quarter, compared to analyst estimates of $168.60 million. Taro Pharmaceutical Industries had a return on equity of 14.13% and a net margin of 40.43%. View Taro Pharmaceutical Industries' Earnings History.

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Taro Pharmaceutical Industries.

1 analysts have issued 12-month price targets for Taro Pharmaceutical Industries' stock. Their forecasts range from $110.00 to $110.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $110.00 in the next year. This suggests a possible upside of 28.6% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

News coverage about TARO stock has trended very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of 3.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Taro Pharmaceutical Industries.

Taro Pharmaceutical Industries saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 163,200 shares, a drop of 20.7% from the December 15th total of 205,900 shares. Based on an average trading volume of 77,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.8% of the company's shares are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Some companies that are related to Taro Pharmaceutical Industries include GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Horizon Therapeutics (HZNP), Amarin (AMRN) and Dr.Reddy's Laboratories (RDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Skyworks Solutions (SWKS), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Supernus Pharmaceuticals (SUPN), Pfizer (PFE), GW Pharmaceuticals PLC- (GWPH), Jazz Pharmaceuticals (JAZZ) and Neurocrine Biosciences (nbix).

Taro Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional shareholders include CLARET ASSET MANAGEMENT Corp (0.22%) and AE Wealth Management LLC (0.01%).

TARO stock was sold by a variety of institutional investors in the last quarter, including CLARET ASSET MANAGEMENT Corp.

TARO stock was bought by a variety of institutional investors in the last quarter, including AE Wealth Management LLC.

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TARO stock can currently be purchased for approximately $85.55.

Taro Pharmaceutical Industries has a market capitalization of $3.27 billion and generates $669.89 million in revenue each year. The company earns $281.78 million in net income (profit) each year or $7.23 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.View Additional Information About Taro Pharmaceutical Industries.

The official website for Taro Pharmaceutical Industries is http://www.taro.com/.

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]